J9362: Injection, trabectedin, 0.01 mg
J9362 is a HCPCS Level II code for injection, trabectedin, 0.01 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J9362
- Long descriptor
- Injection, trabectedin, 0.01 mg
- Short descriptor
- Inj, trabectedin, 0.01 mg
- Added
- October 1, 2026
- BETOS
- O1D
- Pricing indicator
- 51: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Drugs.
Codes adjacent to J9362
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If J9362 is not quite right, the correct code is very often within a few positions of it.
- J9354Injection, ado-trastuzumab emtansine, 1 mg
- J9355Injection, trastuzumab, excludes biosimilar, 10 mg
- J9356Injection, trastuzumab, 10 mg and hyaluronidase-oysk
- J9357Injection, valrubicin, intravesical, 200 mg
- J9358Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
- J9359Injection, loncastuximab tesirine-lpyl, 0.075 mg
- J9360Injection, vinblastine sulfate, 1 mg
- J9361Injection, efbemalenograstim alfa-vuxw, 0.5 mg
- J9370Vincristine sulfate, 1 mg
- J9371Injection, vincristine sulfate liposome, 1 mgterminated
- J9376Injection, pozelimab-bbfg, 1 mg
- J9380Injection, teclistamab-cqyv, 0.5 mg
- J9381Injection, teplizumab-mzwv, 5 mcg
- J9382Injection, zenocutuzumab-zbco, 1 mg
- J9390Injection, vinorelbine tartrate, 10 mg
- J9393Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg